~~<i id='8B1C4204A7'><strike id='8B1C4204A7'><tt id='8B1C4204A7'><pre id='8B1C4204A7'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：fashion 2025-10-01 14:34:38 Page View：75986

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Independent physicians launch a new lobbying group
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Study finds gene variants tied to breast cancer risk in Black women

AdobeHundredsofgeneticvariantscannudgesomeone’sriskofbreastcancerupordownortowardsaparticularsubtype

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

UnitedHealth argues against case alleging wrongful AI care denials

AdobeUnitedHealthGroupshouldbereleasedfromalawsuitthatallegesitsalgorithm-basedtechnologyprematurely